The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement

Medical Principles and Practice

Volumn 17, Issue 6, 2008, Pages 464-467

  Yildirim, Hatice ^a   Tamer, Lülüfer ^a   Sucu, Nehir ^a   Atik, Uǧur ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

CYP2C9 gene polymorphism; Heart valve replacement; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HEART VALVE REPLACEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPLACEMENT; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; WARFARIN; YOUNG ADULT;

EID: 53549101654     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151568     Document Type: Article

References (16)

1. Vongpatanasin W, Hillis D, Lange RA: Prosthetic heart valves. N Engl J Med 1996;335:407-416.
2. Schoen FJ, Levy RJ: Tissue heart valves: current challenges and future research perspectives. J Biomed Mater Res 1999;47:439-465.
3. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-1698.
4. Adcock DM, Koftan C, Crisan D, Kiechle FL: Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation. Arch Pathol Lab Med 2004;128:1360-1363.
5. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(suppl 1):8-21.
6. Penning-van Beest FJA, van Meegen E, Rosendaal FR: Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001;86:569-574.
7. Stroke Prevention in Atrial Fibrillation Investigators: Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-416.
8. Taube J, Halsall D, Baglin T: Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients. Blood 2000;96:1816-1819.
9. Choonara IA, Cholerton S, Haynes BP, Breckenridge AM, Park BK: Stereoselective interaction between the R-enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 1986;21:271-277.
10. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-439.
11. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
12. Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD: The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002;194:267-273.
13. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J: Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-136.
14. Lee CR, Goldstein JA, Pieper JA: Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-263.
15. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-649.
16. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE: Genetic association between sensitivity to warfarin and expression of CYP2C9 * 3. Pharmacogenetics 1997;7:361-367.